Actively Recruiting
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
Led by Second Xiangya Hospital of Central South University · Updated on 2023-04-21
500
Participants Needed
1
Research Sites
573 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The China Alliance for Type 1 Diabetes (CAT1D) is committed to exploring and implementing the model of graded diagnosis and treatment of type 1 diabetes and comprehensive management of outpatient service, carrying out a series of educational activities for patients, and cooperating in the development of multi-center prospective clinical research on type 1 diabetes.
CONDITIONS
Official Title
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals diagnosed with Type 1 Diabetes according to the 1999 World Health Organization report
- Written informed consent from the patient or family representative
- Individuals who own smartphone and are capable of using wechat or apps
You will not qualify if you...
- Non-t1dm patients with autoimmune polyendocrine adenopathy syndrome (APS) are the first disease
- With mental disorders
- Have any other condition or disease that may hamper from compliance with the protocol or complication of the trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University
Changsha, Hunan, China, 410011
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here